Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thompson N Doman

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Plos One|January 18, 2019
Bottom-up, integrated -omics analysis identifies broadly dosage-sensitive genes in breast cancer samples from TCGABobak D Kechavarzi, Huanmei Wu, Thompson N Doman
Journal of Medicinal Chemistry|October 3, 2003
Identification and prediction of promiscuous aggregating inhibitors among known drugsJames Seidler, Susan L McGovern, Thompson N Doman, et al.
Journal of Chemical Information and Modeling|May 5, 2007
3D QSAR methods: Phase and Catalyst comparedDavid A Evans, Thompson N Doman, David A Thorner, et al.
Nature Chemical Biology|January 13, 2006
High-throughput assays for promiscuous inhibitorsBrian Y Feng, Anang Shelat, Thompson N Doman, et al.
Journal of Medicinal Chemistry|May 17, 2002
Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1BThompson N Doman, Susan L McGovern, Bryan J Witherbee, et al.
Journal of Translational Medicine|March 19, 2022
Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimabJonathan T Sims, Josh Poorbaugh, Ching-Yun Chang, et al.
Plos One|July 18, 2022
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor modelsYanxia Li, Nelusha Amaladas, Marguerita O'Mahony, et al.
Plos One|May 31, 2014
Identification of druggable cancer driver genes amplified across TCGA datasetsYing Chen, Jeremy McGee, Xianming Chen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 30, 2021
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced CancerNuria Kotecki, Perrine Vuagnat, Bert H O'Neil, et al.
Journal of Computer-Aided Molecular Design|September 16, 2022
Epilogue to the Gerald Maggiora Festschrift: a tribute to an exemplary mentor, colleague, collaborator, and innovatorVeerabahu Shanmugasundaram, Jürgen Bajorath, Ralph E Christoffersen, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Plos One|January 18, 2019
Bottom-up, integrated -omics analysis identifies broadly dosage-sensitive genes in breast cancer samples from TCGABobak D Kechavarzi, Huanmei Wu, Thompson N Doman
Journal of Medicinal Chemistry|October 3, 2003
Identification and prediction of promiscuous aggregating inhibitors among known drugsJames Seidler, Susan L McGovern, Thompson N Doman, et al.
Journal of Chemical Information and Modeling|May 5, 2007
3D QSAR methods: Phase and Catalyst comparedDavid A Evans, Thompson N Doman, David A Thorner, et al.
Nature Chemical Biology|January 13, 2006
High-throughput assays for promiscuous inhibitorsBrian Y Feng, Anang Shelat, Thompson N Doman, et al.
Journal of Medicinal Chemistry|May 17, 2002
Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1BThompson N Doman, Susan L McGovern, Bryan J Witherbee, et al.
Journal of Translational Medicine|March 19, 2022
Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimabJonathan T Sims, Josh Poorbaugh, Ching-Yun Chang, et al.
Plos One|July 18, 2022
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor modelsYanxia Li, Nelusha Amaladas, Marguerita O'Mahony, et al.
Plos One|May 31, 2014
Identification of druggable cancer driver genes amplified across TCGA datasetsYing Chen, Jeremy McGee, Xianming Chen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 30, 2021
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced CancerNuria Kotecki, Perrine Vuagnat, Bert H O'Neil, et al.
Journal of Computer-Aided Molecular Design|September 16, 2022
Epilogue to the Gerald Maggiora Festschrift: a tribute to an exemplary mentor, colleague, collaborator, and innovatorVeerabahu Shanmugasundaram, Jürgen Bajorath, Ralph E Christoffersen, et al.
Pageof 2